Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jun;41(6):1389–1391. doi: 10.1128/aac.41.6.1389

Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: a phase I study.

L Aguilar 1, J Rosendo 1, I P Balcabao 1, M Martín 1, M J Giménez 1, J Frías 1, J Prieto 1
PMCID: PMC163922  PMID: 9174206

Abstract

Serum bactericidal activity against a penicillin-susceptible strain and a penicillin-resistant strain of Streptococcus pneumoniae (amoxicillin and cefotaxime MICs, 0.001 and 1 microg/ml, respectively, and MBCs, 0.01 and 2 microg/ml, respectively) was measured in 12 healthy volunteers who each received an oral 875-mg dose of amoxicillin and an intramuscular 1-g dose of cefotaxime in a crossover fashion. The areas under the bactericidal activity-time curves for the two strains were found to be similar for both antibiotics despite the significantly higher (P < 0.002) AUC/MIC and peak level/MIC values for cefotaxime.

Full Text

The Full Text of this article is available as a PDF (132.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Ausina V., Coll P., Sambeat M., Puig I., Condom M. J., Luquin M., Ballester F., Prats G. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):342–347. doi: 10.1007/BF01962334. [DOI] [PubMed] [Google Scholar]
  3. Balcabao I. P., Aguilar L., Martín M., García Y., Dal-Ré R., Prieto J. Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation. Antimicrob Agents Chemother. 1996 Dec;40(12):2904–2906. doi: 10.1128/aac.40.12.2904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barriere S. L., Ozasa D. C., Mordenti J. Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects. Antimicrob Agents Chemother. 1985 Jul;28(1):55–57. doi: 10.1128/aac.28.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Friedland I. R., McCracken G. H., Jr Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994 Aug 11;331(6):377–382. doi: 10.1056/NEJM199408113310607. [DOI] [PubMed] [Google Scholar]
  6. Klastersky J., Daneau D., Swings G., Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis. 1974 Feb;129(2):187–193. doi: 10.1093/infdis/129.2.187. [DOI] [PubMed] [Google Scholar]
  7. Klastersky J. The bactericidal activity in serum and its prognostic clinical value. Infection. 1983;11 (Suppl 2):S93–S96. doi: 10.1007/BF01645296. [DOI] [PubMed] [Google Scholar]
  8. Kowalsky S. F., Echols R. M., McCormick E. M. Comparative serum bactericidal activity of ceftizoxime/metronidazole, ceftizoxime, clindamycin, and imipenem against obligate anaerobic bacteria. J Antimicrob Chemother. 1990 May;25(5):767–775. doi: 10.1093/jac/25.5.767. [DOI] [PubMed] [Google Scholar]
  9. Pallares R., Liñares J., Vadillo M., Cabellos C., Manresa F., Viladrich P. F., Martin R., Gudiol F. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995 Aug 24;333(8):474–480. doi: 10.1056/NEJM199508243330802. [DOI] [PubMed] [Google Scholar]
  10. Soriano F., Ponte C., Nieto E., Parra A. Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. J Antimicrob Chemother. 1996 Aug;38(2):227–236. doi: 10.1093/jac/38.2.227. [DOI] [PubMed] [Google Scholar]
  11. Stratton C. W., Weinstein M. P., Reller L. B. Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration. J Infect Dis. 1982 Feb;145(2):160–168. doi: 10.1093/infdis/145.2.160. [DOI] [PubMed] [Google Scholar]
  12. Trautmann M., Ruhnke M., Borner K., Wagner J., Koeppe P. Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. Antimicrob Agents Chemother. 1996 Mar;40(3):776–779. doi: 10.1128/aac.40.3.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wolfson J. S., Swartz M. N. Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med. 1985 Apr 11;312(15):968–975. doi: 10.1056/NEJM198504113121507. [DOI] [PubMed] [Google Scholar]
  14. Zeiler H. J., Beermann D., Wingender W., Förster D., Schacht P. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection. 1988;16 (Suppl 1):S19–S23. doi: 10.1007/BF01650502. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES